Use of compounds that bind to GPR49 for diagnosis and treatment of cancer

摘要

Use of a GPR49 peptide or protein (I), and/or nucleic acid (II) that encodes (I), for detection of cancer (or the risk of developing it), particularly of the colon, uterus and/or rectum, in which an appropriate tissue sample is examined for (over)transcription of GPR49 mRNA or (over)expression of GPR49 protein. Independent claims are also included for the following: (1) use of GPR49 RNA (IIa) or of (I) to screen for binding agents; (2) use of an agent (III) that inhibits, or binds to, GPR49 in preparation of pharmaceutical compositions; (3) method for diagnosing cancer (or risk of developing it) that uses a GPR49-binding detector substance; (4) method for treating cancer using (III); and (5) protein or peptide containing, or comprising, any of the fully defined sequences (SEQ ID NOs: 1, 2, 4-80 or 83) or a partial sequence of minimum fully defined in the specification (SEQ ID NOs: 4, 5, 6, 7, 8, 9, or 10), also the nucleic acids encoding them, as new compounds. SEQ ID NO:5 Gly-Ser-Ser-Pro-Arg-Ser-Gly-Val-Leu SEQ ID NO:6 Ser-Ser-Pro-Arg SEQ ID NO:7 Gly-Cys-Pro-Thr-His SEQ ID NO:8 His-Cys-Glu-Pro-Asp-Gly-Arg-Met SEQ ID NO:9 Glu-Pro-Asp-Gly-Arg-Met SEQ ID NO:10 Glu-Pro-Asp-Gly ACTIVITY : Cytostatic. No details of tests for cytostatic activity are given. MECHANISM OF ACTION : G protein coupled receptor antagonist; GPR49 antagonist; Antisense oligonucleotide inhibitor; RNA interference; RNAi.